Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on January 17, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi212
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/1/17    most recent
hyi212v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ryu, M.-H.
Right arrow Articles by Kang, Y.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryu, M.-H.
Right arrow Articles by Kang, Y.-K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 Foundation for Promotion of Cancer Research
Received August 17, 2005
Accepted November 29, 2005

Article

Patterns of Progression in Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate

Min-Hee Ryu 1, Jae-Lyun Lee 1, Heung Moon Chang 1, Tae Won Kim 1, Hye Jin Kang 1, Hee Jung Sohn 1, Jung Shin Lee 1, and Yoon-Koo Kang 1 *

1 Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

* To whom correspondence should be addressed.
Yoon-Koo Kang, E-mail: ykkang{at}amc.seoul.kr


  Abstract

Background: Although most patients with gastrointestinal stromal tumor (GIST) treated with imatinib mesylate achieve remission or disease stabilization, a significant proportion show progressive disease (PD) with or without initial favorable responses. We evaluated and categorized the patterns of progression of metastatic or unresectable GIST treated with imatinib to identify the prognostic significance and contribution to further treatment decision-making.

Methods: We prospectively gathered clinical data from 62 GIST patients treated with imatinib mesylate (400 mg/day) over a median period of 26 months. Twenty-one of these patients showed evidence of PD based on Response Evaluation Criteria in Solid Tumor criteria.

Results: Four patterns of PD were defined: focal progression (FP, N = 4), general progression (GP, N = 6), new cystic lesion (NCL, N = 6) and new solid lesion (NSL, N = 5). The groups were found to differ in terms of time to progression and prior response to imatinib. The proportion of patients who responded to escalated doses of imatinib (600-800 mg/day) was significantly higher in NCL patients (P = 0.04). Overall survival and survival from the confirmation of PD were significantly better in NCL or FP patients compared with NSL or GP patients (P = 0.0157, P = 0.0013).

Conclusions: We identified four patterns of disease progression based on radiographic criteria with different clinical characteristics and impact on survival. Knowledge of these patterns was relevant for early detection and may be helpful in further treatment decision-making.

Keywords: gastrointestinal stromal tumor; imatinib; disease progression; sarcoma; tomography; spiral computed; prognosis.
The first two authors contributed equally to this work.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
T. W. Kim, M.-H. Ryu, H. Lee, S. J. Sym, J.-L. Lee, H. M. Chang, Y. S. Park, K. H. Lee, W. K. Kang, D. B. Shin, et al.
Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors
Oncologist, May 1, 2009; 14(5): 540 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Park, M.-H. Ryu, S. J. Sym, S. S. Lee, G. Jang, T. W. Kim, H. M. Chang, J.-L. Lee, H. Lee, and Y.-K. Kang
Dose Escalation of Imatinib After Failure of Standard Dose in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor
Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 105 - 110.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J.-L. Lee, M.-H. Ryu, H. M. Chang, T. W. Kim, H. J. Kang, H. J. Sohn, J. S. Lee, and Y.-K. Kang
Clinical Outcome in Gastrointestinal Stromal Tumor Patients who Interrupted Imatinib after Achieving Stable Disease or Better Response
Jpn. J. Clin. Oncol., November 1, 2006; 36(11): 704 - 711.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.